Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
复制标题
DOI：
10.3324/haematol.2012.069393
复制
发表时间：
2013-04-01
期刊：
影响因子：
10.1
通讯作者：
Radford, John
中科院分区：
文献类型：
--
作者：
Gibb, Adam;Jones, Craig;Radford, John
在II期研究中，CD 30靶向药物维布妥昔单抗在复发性/难治性霍奇金淋巴瘤和间变性大细胞淋巴瘤中显示出令人印象深刻的活性。2010- 2011年期间，我们在一家英国中心治疗了24例复发性/难治性疾病患者，这些患者入选了指定患者项目。所有组织学类型的总体缓解率为67%（霍奇金淋巴瘤72%;间变性大细胞淋巴瘤60%），完全缓解率为25%（霍奇金淋巴瘤17%;间变性大细胞淋巴瘤60%），中位无进展生存期为5.1个月，大多数病例的毒性为轻度至中度。6名患者进行了同种异体移植，1名患者等待该程序。这些结果与II期数据相似，表明维布妥昔单抗为约四分之一的传统挽救治疗难治性患者提供了异基因移植的桥梁。四剂后观察到最佳反应，因此应尽早考虑同种异体移植，并在第一次评估表明反应后安排。
The CD30-targeted agent brentuximab vedotin has shown impressive activity in relapsed/refractory Hodgkin lymphoma and anaplastic large cell lymphoma in phase II studies. We have treated 24 patients with relapsed/refractory disease enrolled onto a Named Patient Programme during 2010-11 at a single UK center. Overall response rate across all histologies was 67% (Hodgkin 72%; anaplastic large cell 60%), complete response rate 25% (Hodgkin 17%; anaplastic large cell 60%), median progression-free survival 5.1 months, and toxicity mild to moderate in the majority of cases. Six patients proceeded to allogeneic transplantation and one patient awaits this procedure. These results are similar to phase II data and show that brentuximab vedotin provides a bridge to allogeneic transplantation in approximately one quarter of patients refractory to conventional salvage therapies. Best response was seen after four doses, so consideration of allogeneic transplantation should be made early and scheduled following the first assessment indicating response.